Edoxaban: A New Oral Direct Factor Xa Inhibitor

By Camm A. John  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1503-1526

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Absence of Clinically Relevant Interactions between Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects

By Kubitza D   Becka M   Roth A   Mueck W  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1688-1707

Field House Publishing

Access to resources Recommend Favorite

A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 11, 2015-11 ,pp. : 650-659

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 349-357

John Wiley & Sons Inc

Access to resources Recommend Favorite